Trevi Therapeutics, Inc. (TRVI) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	20.9	20.4	19.8	19.6	19.2	14.0	9.5	10.0
Sales and marketing	15.9	15.4			14.8	7.0
General and administrative			5.0	4.7			9.5	10.0
Research and development			10.1	11.9			23.0	23.4
Other operating expenses	-3.4	-0.5			1.1	0.6
EBITDA [+]	-27.6	-29.9	-31.0	-32.6	-31.2	-32.0	-32.5	-33.3
EBITDA growth	-11.5%	-6.6%	-4.6%	-2.2%	-7.4%	0.4%	0.1%	11.1%
Depreciation and amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
EBIT [+]	-27.6	-29.9	-31.0	-32.6	-31.2	-32.0	-32.5	-33.4
EBIT growth	-11.4%	-6.6%	-4.6%	-2.3%	-7.5%	0.3%	0.0%	11.1%
Interest expense			0.6	0.6			1.2	1.2
Interest expense	0.6	0.6	0.6	0.6	0.6	0.9	1.2	1.2
Other income (expense), net [+]	0.8	2.2	2.4	1.0	0.6	0.0	-0.3	-0.3
Other		0.2
Pre-tax income	-27.4	-28.3	-29.2	-32.2	-31.2	-32.9	-34.0	-34.9
Income taxes	-0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.2%	0.1%	0.1%	0.1%	0.0%	0.0%	0.1%
Net income	-27.3	-28.2	-29.2	-32.2	-31.2	-32.9	-33.9	-34.9

Basic EPS [+]	($0.33)	($0.39)	($0.52)	($0.71)	($0.92)	($1.38)	($1.62)	($1.76)
Growth	-64.3%	-71.9%	-67.8%	-60.0%	-50.1%	-22.4%	-11.3%	-2.9%
Diluted EPS [+]	($0.33)	($0.39)	($0.52)	($0.71)	($0.92)	($1.38)	($1.62)	($1.76)
Growth	-64.3%	-71.9%	-67.8%	-60.0%	-50.1%	-22.4%	-11.3%	-2.9%

Shares outstanding (basic) [+]	82.7	72.9	55.9	45.5	33.7	23.8	21.0	19.8
Growth	145.4%	205.7%	166.4%	129.9%	78.0%	29.9%	16.9%	20.9%
Shares outstanding (diluted) [+]	82.7	72.9	55.9	45.5	33.7	23.8	21.0	19.8
Growth	145.4%	205.7%	166.4%	129.9%	78.0%	29.9%	16.9%	20.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.